In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly and Company

https://www.lilly.com/

Latest From Eli Lilly and Company

Structure Emerges In Obesity Race With Oral GLP-1 Agonist

Early-stage data with Structure’s oral GSBR-1290 shows weight loss of 4.9% at four weeks, which appears to top Lilly’s oral GLP-1 data in a Phase Ia trial.

Clinical Trials Business Strategies

Imbruvica, Enbrel, Stelara Offer Best Chance Of Savings From Medicare Negotiation In First Round

The other seven drugs on the initial list for negotiation are already heavily rebated and CMS could choose not to go much lower than current net prices, SSR Health report points out.

Reimbursement Pricing Debate

Novo Nordisk Looks To Bring AI/ML To Cardiometabolic Disease In Valo Health Deal

Deal Snapshot: The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform.

Artificial Intelligence Deals

Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS

Deal Snapshot: Looking to add to its neuroscience pipeline, Takeda acquires rights to the antisense candidate AS-202 from AcuraStem for development as a potential amyotrophic lateral sclerosis therapy.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Akouos, Inc.
    • Alnara Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc.
    • Applied Molecular Evolution
    • Avid Radiopharmaceuticals, Inc.
    • Bowfin Acquisition Corporation
    • Class AP
    • CoLucid Pharmaceuticals, Inc.
    • Dermira Inc.
    • Disarm Therapeutics, Inc.
    • Hypnion
    • ICOS Corporation
    • ImClone Systems
    • Loxo Oncology, Inc. (LOXO)
    • Protomer Technologies
    • SGX Pharmaceuticals (Structural GenomiX)
    • Valocor Therapeutics, Inc.
UsernamePublicRestriction

Register